About Subhasree Kar
Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics.
She uses her knowledge as a fundamental analyst to help investors make informed decisions in regards to their investment portfolios.
Recent Articles By Subhasree Kar
Is Constellation Brands (STZ) a Beverage Stock BUY?
Although Constellation Brands (STZ) has witnessed steady topline growth, high inflation, and elevated operating costs have been causing a consistent squeeze on its profit margins. So, is this alcoholic beverage stock worth buying? Keep reading...
Is Marine Products Corporation (MPX) the #1 Leisure Stock Pick?
Marine Products (MPX) was a significant beneficiary of the recreational boating wave following the pandemic. With the recreational boating industry expected to flourish this summer, is MPX the top choice in the leisure industry? Read on...
Is There a Chance of Growth in Peloton Interactive (PTON)?
While exercise equipment maker Peloton Interactive (PTON) has witnessed declining sales post-pandemic, it is taking significant initiatives as part of its turnaround efforts. Will the company be able to achieve sustainable growth? Read on...
Should You Buy Shares of Cronos Group (CRON) in July?
Cannabis producer Cronos Group (CRON) is experiencing turbulent times with weakening sales and losses. So, will it be worth investing in the stock now? Read on...
Is Nike (NKE) a Quality Stock?
NIKE (NKE) faces margin pressures as consumers pull back on spending amid recession concerns. The company saw a significant decline in its bottom line in the last reported quarter. So, will it be worth investing in this sportswear giant now? Keep reading...
ContextLogic (WISH): Is it a Buy or Sell
Mobile e-commerce company ContextLogic (WISH) has been plagued by declining revenues and widening losses. While the company ramps up efforts to stage a turnaround, let’s analyze whether you should Buy or Sell the stock at the moment...
Is Catalyst Pharmaceuticals (CPRX) a Quality Investment?
Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) delivered a robust performance in the first quarter of 2023. However, it fell short of analysts’ estimates. Let’s dig into some of its financial metrics to determine whether CPRX is worth buying ahead of the upcoming earnings season...
Should You Watch Bionano Genomics (BNGO) this Week?
While Bionano Genomics (BNGO) is witnessing steady revenue growth, its bottom line remains in the red. Let’s dive deeper into its key financial metrics to analyze if BNGO is worth adding to your watchlists...
Clover Health Investments (CLOV): Buy, Hold or Sell End of June?
Clover Health (CLOV) has been subject to several lawsuits and federal investigations. Also, the company’s bottom line is in the red. However, CLOV is ramping up its efforts to accelerate its path to profitability. So, should you Buy, Hold or Sell the stock now? Read on to learn my views...